Cited by 113Atrial Fibrillation Management and OutcomesHeart Failure Treatment and ManagementCardiac Health and Mental Health

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Digoxin and mortality in atrial fibrillation: a prospective cohort study

Hallberg, Pär, Lindbäck, Johan, Lindahl, Bertil, Stenestrand, Ulf, Melhus, Håkan, for the RIKS-HIA group·2007·European Journal of Clinical Pharmacology

DOI 10.1007/s00228-007-0346-9

Open this paper in CoChat — free account

Abstract

Objective The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study showed that rhythm-control treatment of patients with atrial fibrillation (AF) offered no survival advantage over a rate-control strategy. In a subgroup analysis of that study, it was found that digoxin increased the death rate [relative risk (RR) = 1.42), but it was suggested that this may have been attributable to prescription of digoxin for patients at greater risk of death, such as those with congestive heart failure (CHF). No study has investigated a priori the effect of digoxin on mortality in patients with AF. This study aimed to address this question.Methods Using data from the Registry of Information and Knowledge about Swedish Heart Intensive care Admissions (RIKS-HIA), we studied the 1-year mortality among patients admitted to coronary care units with AF, CHF, or AF+CHF with or without digoxin (n = 60,764) during 1995-2003. Adjustment for differences in background characteristics and other medications and treatments was made by propensity scoring.Results Twenty percent of patients with AF without CHF in this cohort were discharged with digoxin. This group had a higher mortality rate than the corresponding group not given digoxin [adjusted RR 1.42 (95% CI 1.29-1.56)], whereas no such difference was seen among patients with CHF with or without AF, although these patients had a nearly three-times higher mortality.Conclusion The results suggest that long-term therapy with digoxin is an independent risk factor for death in patients with AF without CHF.

Integrity signals

Registry

Crossref · 10.1007/s00228-007-0346-9

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
A comparison of rate control and rhythm control in patients with atrial fibrillation
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa021328 · Cited by 4,405
Estimating Causal Effects from Large Data Sets Using Propensity Scores
Rubin, D. V. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-8_part_2-199710151-00064 · Cited by 3,104
The effect of digoxin on mortality and morbidity in patients with heart failure
(1997) · New England Journal of Medicine · doi:10.1056/nejm199702203360801 · Cited by 3,016
Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study
The AFFIRM Investigators (2004) · Circulation · doi:10.1161/01.cir.0000121736.16643.11 · Cited by 1,202
Invited commentary: propensity scores.
Joffe, M., & Rosenbaum, P. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010011 · Cited by 1,117
Predictors of mortality and morbidity in patients with chronic heart failure
Pocock, S., Wang, D., Pfeffer, M. A., Yusuf, S., McMurray, J. J. V., Swedberg, K. B., Östergren, J., Michelson, E. L., Pieper, K. S., & Granger, C. B. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi555 · Cited by 972
Risk of Death in Elderly Users of Conventional vs. Atypical Antipsychotic Medications
Wang, P. S., Schneeweiss, S., Avorn, J., Fischer, M. A., Mogun, H., Solomon, D. H., & Brookhart, M. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052827 · Cited by 959
Digoxin in Heart Failure with a Reduced Ejection Fraction: A Risk Factor or a Risk Marker?
Konstantinou, D. M., Karvounis, H. I., & Giannakoulas, G. A. (2016) · Cardiology · doi:10.1159/000444078 · Cited by 881

Show all 44 references

Sorted by citations

2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström‐Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 10,550
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P. F., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castellà, M., Diener, H., Heidbüchel, H., Hendriks, J., et al. (2016) · EP Europace · doi:10.1093/europace/euw295 · Cited by 6,438
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw313 · Cited by 1,403
Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data
Ziff, O. J., Lane, D. A., Samra, M., Griffith, M., Kirchhof, P., Lip, G. Y. H., Steeds, R. P., Townend, J., & Kotecha, D. (2015) · BMJ · doi:10.1136/bmj.h4451 · Cited by 341
Digoxin-associated mortality: a systematic review and meta-analysis of the literature
Vámos, M., Erath, J. W., & Hohnloser, S. H. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv143 · Cited by 302
Increased mortality among patients taking digoxin—analysis from the AFFIRM study
Whitbeck, M. G., Charnigo, R. J., Khairy, P., Ziada, K., Bailey, A. L., Zegarra, M. M., Shah, J., Morales, G., Macaulay, T., Sorrell, V. L., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs348 · Cited by 279
Digoxin and Mortality in Patients With Atrial Fibrillation
Lópes, R. D., Rordorf, R., Ferrari, G. M. D., Leonardi, S., Thomas, L. E., WOJDYLA, D. M., Ridefelt, P., Lawrence, J. H., Caterina, R. D., Vinereanu, D., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.12.060 · Cited by 218
Comorbidity of atrial fibrillation and heart failure
Ling, L., Kistler, P. M., Kalman, J. M., SCHILLING, R. J., & Hunter, R. J. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.191 · Cited by 217
Increased Mortality Associated With Digoxin in Contemporary Patients With Atrial Fibrillation
Turakhia, M. P., Santangeli, P., Winkelmayer, W. C., Xu, X., Ullal, A. J., Than, C. T., Schmitt, S., Holmes, T. H., Frayne, S. M., Phibbs, C. S., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.060 · Cited by 208
Rate control in atrial fibrillation
Gelder, I. C. V., Rienstra, M., Crijns, H. J. G. M., & Olshansky, B. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31258-2 · Cited by 212
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Washam, J. B., Stevens, S. R., Lokhnygina, Y. V., Halperin, J. L., BREITHARDT, G. E., Singer, D. E., Mahaffey, K. W., Hankey, G. J., Berkowitz, S. D., Nessel, C. C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61836-5 · Cited by 146
Digoxin: The good and the bad
Ziff, O. J., & Kotecha, D. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.03.011 · Cited by 144
Meta-Analysis of Digoxin Use and Risk of Mortality in Patients With Atrial Fibrillation
Ouyang, A.-J., Lv, Y.-N., Zhong, H.-L., Wen, J.-H., Wei, X.-H., Peng, H.-W., Zhou, J. H., & Liu, L.-L. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.01.013 · Cited by 99
Managing atrial fibrillation in the very elderly patient: challenges and solutions
Letsas, Κ. P., Karamichalakis, N., Vlachos, K. G., Georgopoulos, S., Bakalakos, A., Efremidis, M., & Sideris, A. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s83664 · Cited by 86
Digoxin and Risk of Death in Adults With Atrial Fibrillation
Freeman, J. V., Reynolds, K., Fang, M. C., Udaltsova, N. V., Steimle, A. E., Pomernacki, N. K., Borowsky, L. H., Harrison, T. N., Singer, D. E., & Go, A. S. (2014) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.114.002292 · Cited by 82
Interaction Between Digoxin and Dronedarone in the PALLAS Trial
Hohnloser, S. H., Halperin, J. L., Camm, A. J., Gao, P., Radzik, D., & Connolly, S. J. (2014) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.114.002046 · Cited by 77
Digoxin–mortality: randomized vs. observational comparison in the DIG trial
Dávila, L. A., Weber, K., Bavendiek, U., Bauersachs, J. K., Wittes, J. T., Yusuf, S., & Koch, A. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz395 · Cited by 77
Comparison of Beta Blocker and Digoxin Alone and in Combination for Management of Patients With Atrial Fibrillation and Heart Failure
Fauchier, L., Grimard, C., Pierre, B., Nonin, E., Gorin, L., Rauzy, B., Cosnay, P., Babuty, D., & Charbonnier, B. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.09.064 · Cited by 77
Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people
Hanon, O., Assayag, P., Belmin, J., Collet, J., Émeriau, J. P., Fauchier, L., Forette, F., Friocourt, P., Gentric, A., Leclercq, C., et al. (2013) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2013.04.001 · Cited by 72
Relation of Digoxin Use in Atrial Fibrillation and the Risk of All-Cause Mortality in Patients ≥65 Years of Age With Versus Without Heart Failure
Shah, M., Tsadok, M. A., Jackevicius, C. A., Essebag, V., Behlouli, H., & Pilote, L. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.05.013 · Cited by 66
Prognostic impact of early ventricular fibrillation in patients with ST-elevation myocardial infarction treated with primary PCI
Demidova, M. M., Smith, J. G., Höijer, C. J., Holmqvist, F., Erlinge, D., & Platonov, P. G. (2012) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872612463553 · Cited by 65
Digoxin in atrial fibrillation: report from the Stockholm Cohort study of Atrial Fibrillation (SCAF)
Friberg, L., Hammar, N., & Rosenqvist, M. (2009) · Heart · doi:10.1136/hrt.2009.175786 · Cited by 63
Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction
Virgadamo, S. (2015) · World Journal of Cardiology · doi:10.4330/wjc.v7.i11.808 · Cited by 57
Association is not causation: treatment effects cannot be estimated from observational data in heart failure
Rush, C. J., Campbell, R. T., Jhund, P. S., Petrie, M. C., & McMurray, J. J. V. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy407 · Cited by 52
Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF‐TIMI 48 Trial
Eisen, A., Ruff, C. T., D, E. B. M., Hamershock, R. A., Lewis, B. S., Hassager, C., Chao, T., Heuzey, J. Y. L., Mercuri, M. F., Rutman, H., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006035 · Cited by 48
Does Digoxin Increase the Risk of Ischemic Stroke and Mortality in Atrial Fibrillation? A Nationwide Population-Based Cohort Study
Chao, T., Liu, C., Chen, S., Wang, K.-L., Lin, Y., Chang, S., Lo, L., Hu, Y., Tuan, T., Chen, T., et al. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.05.009 · Cited by 45
In vitro culture of Digitalis L. (Foxglove) and the production of cardenolides: An up-to-date review
Verma, S. K., Das, A. K., Cingoz, G. S., & Gürel, E. (2016) · Industrial Crops and Products · doi:10.1016/j.indcrop.2016.08.031 · Cited by 44
Digoxin in patients with atrial fibrillation and heart failure: A meta-analysis
Bavishi, C., Khan, A. R., & Ather, S. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.031 · Cited by 39
Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation
Pastori, D., Farcomeni, A., Bucci, T., Cangemi, R., Ciacci, P., Vicario, T., Violi, F., & Pignatelli, P. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.11.112 · Cited by 38
Systematic review and meta-analysis of mortality and digoxin use in atrial fibrillation
Qureshi, W., O’Neal, W. T., Soliman, E. Z., & Al-Mallah, M. H. (2016) · Cardiology Journal · doi:10.5603/cj.a2016.0016 · Cited by 33
Digoxin Is Associated With Increased All-cause Mortality in Patients With Atrial Fibrillation Regardless of Concomitant Heart Failure
Wang, Z., Zhang, R., Chen, M.-T., Wang, Q., Zhang, Y., Huang, X., Wang, J., Yan, J., & Li, Y. (2015) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000274 · Cited by 32
Current Drug Treatment Strategies for Atrial Fibrillation and TASK-1 Inhibition as an Emerging Novel Therapy Option
Kraft, M., Büscher, A., Wiedmann, F., L’hoste, Y., Haefeli, W. E., Frey, N., Katus, H. A., & Schmidt, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.638445 · Cited by 31
Does intensity of rate control influence outcome in persistent atrial fibrillation?
Groenveld, H. F., Crijns, H. J. G. M., Rienstra, M., van den Berg, M. P., van Veldhuisen, D. J., & Gelder, I. C. V. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.09.007 · Cited by 29
Guía ESC 2020 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración de la European Association of Cardio-Thoracic Surgery (EACTS)
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström‐Lundqvist, C., Boriani, G., Castellà, M., Dan, G., Dilaveris, P., et al. (2021) · Revista Española de Cardiología · doi:10.1016/j.recesp.2020.10.022 · Cited by 34
Role of Digoxin in Atrial Fibrillation
Scalese, M. J., & Salvatore, D. J. (2016) · Journal of Pharmacy Practice · doi:10.1177/0897190016642361 · Cited by 28
Digoxin in Atrial Fibrillation: An Old Topic Revisited
Ferrari, F., Santander, I. R. M. F., & Stein, R. (2019) · Current Cardiology Reviews · doi:10.2174/1573403x15666190618110941 · Cited by 27
Digoxin and clinical outcomes in the Global Rheumatic Heart Disease Registry
Karthikeyan, G., Devasenapathy, N., Zuhlke, L. J., Engel, M. E., Rangarajan, S., Teo, K. K., Mayosi, B. M., & Yusuf, S. (2018) · Heart · doi:10.1136/heartjnl-2018-313614 · Cited by 26
Safety of Intravenous Diltiazem in Reduced Ejection Fraction Heart Failure with Rapid Atrial Fibrillation
Jandali, M. B. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0631-7 · Cited by 25
Effects of digitalis on mortality in a large cohort of implantable cardioverter defibrillator recipients: results of a long-term follow-up study in 1020 patients
Erath, J. W., Vámos, M., & Hohnloser, S. H. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw008 · Cited by 21
Is There an Association Between External Cardioversions and Long-Term Mortality and Morbidity?
Elayi, C. S., Whitbeck, M. G., Charnigo, R. J., Shah, J. S., Macaulay, T. E., MORALES, G. X., Gurley, J. C., Kakavand, B., Thal, S. G., Ching, C. K., et al. (2011) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.110.960591 · Cited by 21
The impact of digoxin on mortality in patients with chronic systolic heart failure: A propensity-matched cohort study
Khateeb, M. A., Qureshi, W., Odeh, R., Ahmed, A. M., Sakr, S., Elshawi, R., Bdeir, M. B., & Al-Mallah, M. H. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.021 · Cited by 21
Increased All-Cause Mortality Associated With Digoxin Therapy in Patients With Atrial Fibrillation
Chen, Y., Cai, X., Huang, W., Wu, Y., Huang, Y., & Hu, Y. (2015) · Medicine · doi:10.1097/md.0000000000002409 · Cited by 20
Effect of Chronic Kidney Diseases on Mortality among Digoxin Users Treated for Non-Valvular Atrial Fibrillation: A Nationwide Register-Based Retrospective Cohort Study
Sessa, M., Mascolo, A., Andersen, M. P., Rosano, G. M. C., Rossi, F., Capuano, A., & Torp-Pedersen, C. T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160337 · Cited by 19
Digoxin Use to Control Ventricular Rate in Patients with Atrial Fibrillation and Heart Failure Is Not Associated with Increased Mortality
Chamaria, S., Desai, A., Reddy, P. C., Olshansky, B., & Dominic, P. S. (2015) · Cardiology Research and Practice · doi:10.1155/2015/314041 · Cited by 19
Seguimiento clínico de una muestra contemporánea de pacientes con fibrilación auricular en tratamiento con digoxina: resultados del estudio AFBAR
Rodríguez‐Mañero, M., Otero-Raviña, F., García‐Seara, J., Zugaza-Gurruchaga, L., Rodríguez-García, J. M., Blanco-Rodríguez, R., Turrado, V. T., Fernández-Villaverde, J. M., Vidal-Pérez, R., & González‐Juanatey, J. R. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.01.015 · Cited by 18
Beta-blockers or Digoxin for Atrial Fibrillation and Heart Failure?
Fauchier, L., Laborie, G., Clémenty, N., & Babuty, D. (2016) · Cardiac failure review · doi:10.15420/cfr.2015:28:2 · Cited by 18
Drug-induced maculopathy
Khan, M. J., Papakostas, T. D., Kovacs, K. D., & Patel, M. M. (2020) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000714 · Cited by 18
Digoxin and prognosis of heart failure in older patients with preserved ejection fraction: Importance of heart rate. Results from an observational and multicenter study
Llàcer, P., Núñez, J. E., Bayés‐Genís, A., Martel, A. C., Cabanes-Hernández, Y., Díez‐Manglano, J., Rocha, P. Á., Rangel, L. S., del Olmo, V. G., Manzano, L., et al. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.10.010 · Cited by 17
Outcomes of a Contemporary Sample of Patients With Atrial Fibrillation Taking Digoxin: Results From the AFBAR Study
Rodríguez‐Mañero, M., Otero-Raviña, F., García‐Seara, J., Zugaza-Gurruchaga, L., Rodríguez-García, J. M., Blanco-Rodríguez, R., Turrado, V. T., Fernández-Villaverde, J. M., Vidal-Pérez, R., & González‐Juanatey, J. R. (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2014.01.014 · Cited by 16
Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation
Okin, P. M., Hille, D. A., Wachtell, K., Kjeldsen, S. E., Boman, K., Dahlöf, B., & Devereux, R. B. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000559 · Cited by 16
Expert consensus of the French society of geriatrics and gerontology and the French society of cardiology on the management of atrial fibrillation in elderly people
Hanon, O., Assayag, P., Belmin, J., Collet, J., Émeriau, J. P., Fauchier, L., Forette, F., Friocourt, P., Gentric, A., Leclercq, C., et al. (2013) · Gériatrie et Psychologie Neuropsychiatrie du Viellissement · doi:10.1684/pnv.2013.0407 · Cited by 16
Role of digoxin in controlling the ventricular rate during atrial fibrillation: a systematic review and a rethinking
Maury, P., Rollin, A., Galinier, M., & Juillière, Y. (2014) · Research Reports in Clinical Cardiology · doi:10.2147/rrcc.s44919 · Cited by 16
Digoxin Impact on Heart Failure Patients with Atrial Fibrillation
Gerakaris, A., Mulita, F., Koniari, I. C., Artopoulou, E., Mplani, V., Tsigkas, G., Abo-Elseoud, M., Kounis, N. G., & Velissaris, D. (2022) · Medical Archives · doi:10.5455/medarh.2022.76.23-28 · Cited by 15
Impact of Digoxin on Mortality in Patients With Atrial Fibrillation Stratified by Heart Failure
Al-Zakwani, I. S., Panduranga, P., Zubaid, M., Sulaiman, K., Rashed, W. A., Alsheikh-Ali, A. A. A., Almahmeed, W. A., Shehab, A., Qudaimi, A. A., Asaad, N., et al. (2015) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248415603505 · Cited by 14
Digoxin: time to take the gloves off?
Eade, E., Cooper, R., & Mitchell, A. R. J. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.07.034 · Cited by 13
Is Foxglove Effective in Heart Failure?
Chaggar, P. S., Shaw, S. M., & Williams, S. G. (2015) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12130 · Cited by 13
Fibrotic expression profile analysis reveals repurposed drugs with potential anti-fibrotic mode of action
Karatzas, E., Kakouri, A. C., Kolios, G. C., Delis, A., & Spyrou, G. M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249687 · Cited by 12
Design, synthesis, and negative inotropic evaluation of 4‐phenyl‐1H‐1,2,4‐triazol‐5(4H)‐one derivatives containing triazole or piperazine moieties
Wei, Z., Cui, B., Cui, X., Wu, Y., Fu, Y., Liu, L., & Piao, H. (2016) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12828 · Cited by 12
Effect of Digoxin Therapy on Mortality in Patients With Atrial Fibrillation: An Updated Meta-Analysis
Wang, X., Luo, Y., Xu, D., & Zhao, K. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.731135 · Cited by 11
An Updated Review of the Management of Chronic Heart Failure in Patients with Chronic Kidney Disease
Tumelty, E. H., Chung, I., Hussain, S., Ali, M. A., Addada, H., & Banerjee, D. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2504144 · Cited by 11
Rate Control versus Rhythm Control in Atrial Fibrillation: Lessons Learned from Clinical Trials of Atrial Fibrillation
Waldo, A. L. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.08.006 · Cited by 10
Estudio sobre los efectos adversos de los fármacos antiarrítmicos en pacientes con fibrilación auricular atendidos en un Centro de Atención Primaria
Benito, L., Hoyo, J., Montroig, A., Fornés, B., Fluxà, G., Martí, D., Pedrós, M., Sisó‐Almirall, A., Mont, L., Miró, Ò., et al. (2011) · Medicina Clínica · doi:10.1016/j.medcli.2010.06.034 · Cited by 10
Digoxin use is associated with increased risk of stroke in patients with non-valvular atrial fibrillation — a nationwide population-based cohort study
Chang, S., Chang, K., Wang, Y.-C., Muo, C., Pai, P., Chang, C.-B., Li, C., & Sung, F.-C. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.08.103 · Cited by 9
A Comparison of Rate Control Agents for the Treatment of Atrial Fibrillation: Follow-Up Investigation of the AFFIRM Study
Zaman, N., Naccarelli, G. V., & Foy, A. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420987451 · Cited by 9
Synthesis and Positive Inotropic Evaluation of (E)‐2‐(4‐Cinnamylpiperazin‐1‐yl)‐N‐(1‐substituted‐4,5‐dihydro‐[1,2,4]triazolo[4,3‐a]quinolin‐7‐yl)acetamides
Wu, Y., Ma, L., Niu, T., Meng, F., Cui, X., & Piao, H. (2012) · Archiv der Pharmazie · doi:10.1002/ardp.201200159 · Cited by 9
Deleterious cardiovascular effect of exosome in digitalis‐treated decompensated congestive heart failure
Fu, J., Yu, Q., Li, M.-D., Hu, C., & Shi, G. (2020) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22462 · Cited by 8
Metoclopramide and Digoxin Cause 22 Episodes of Bradyarrhythmias
Schwartz, B. G. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.10.016 · Cited by 8
Digitalis therapy is associated with higher comorbidities and poorer prognosis in patients undergoing ablation of atrial arrhythmias: data from the German Ablation Registry
Frommeyer, G., Brachmann, J., İnce, H., Spitzer, S. G., Thomas, D., Willems, S., Schumacher, B. M., Schirdewahn, P., Lewalter, T., Hochadel, M., et al. (2019) · Clinical Research in Cardiology · doi:10.1007/s00392-019-01442-w · Cited by 8
Is rate more important than rhythm in treating atrial fibrillation? No
Mitchell, A. R. J. (2009) · BMJ · doi:10.1136/bmj.b3174 · Cited by 8
Predictors of digoxin use and risk of mortality in ED patients with atrial fibrillation
Wu, S., Yang, Y., Zhu, J., Ren, J., Wang, J., Zhang, H., & Shao, X. (2017) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2017.04.070 · Cited by 8
Digoxin-amiodarone Combination is Associated With Excess All-cause Mortality in Patients With Atrial Fibrillation
Chiang, J., Chen, P., Yang, Y., Chang, C., Chu, F.-Y., Chen, J., Wu, C., Hwang, J., Chiang, F., Lin, L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-61065-4 · Cited by 8
Appropriateness of serum digoxin levels
Lippi, G., Salvagno, G. L., Montagnana, M., Brocco, G., & Guidi, G. C. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0379-0 · Cited by 8
Chronic digitalis therapy in patients before heart transplantation is an independent risk factor for increased posttransplant mortality
Rivinius, R., Helmschrott, M., Ruhparwar, A., Rahm, A., Darche, F. F., Thomas, D., Bruckner, T., Ehlermann, P., Katus, H. A., & Doesch, A. O. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s147062 · Cited by 7
Outcomes With Digoxin in Atrial Fibrillation
Reynolds, M. R. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.04.070 · Cited by 7
Atrial fibrillation in myocardial infarction: predictors and prognosis
Tilling, L., & Clapp, B. R. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02061.x · Cited by 6
The Progress Towards the Development of DHQO Derivatives and Related Analogues with Inotropic Effects
Wu, Y., & Piao, H. (2013) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/13895575113136660089 · Cited by 6
Influence of digoxin on mortality in patients with atrial fibrillation: Overview of systematic reviews
Baker, W. L., Sobieraj, D. M., & DiDomenico, R. J. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2510 · Cited by 6
The Aged Heart
Magidson, P. D. (2022) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2022.06.004 · Cited by 6
Synthesis and positive inotropic evaluation of N-(1-oxo-1,2,4,5-tetrahydro-[1,2,4]triazolo[4,3-a]quinolin-7-yl)acetamides bearing piperazine and 1,4-diazepane moieties
Wu, Y., Ma, L., Niu, T.-W., Cui, X., & Piao, H. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.05.049 · Cited by 6
Beta-blocker treatment in heart failure patients with atrial fibrillation: challenges and perspectives.
Chourdakis, E., Koniari, I. C., Velissaris, D., Tsigkas, G., Kounis, N., & Osman, N. (2021) · PubMed Central · doi:10.11909/j.issn.1671-5411.2021.05.008 · Cited by 6
Timed use of digoxin prevents heart ischemia–reperfusion injury through a REV-ERBα–UPS signaling pathway
Vinod, M., Berthier, A., Maréchal, X., Gheeraert, C., Boutry, R., Delhaye, S., Annicotte, J., Duez, H., Hovasse, A., Cianférani, S., et al. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00148-z · Cited by 5
Association Between Digoxin Use and Adverse Outcomes Among Patients in the Chinese Atrial Fibrillation Registry
Gao, Y., Chang, S., Du, X., Dong, J., Xu, X., Zhou, Y., Lip, G. Y. H., & Ma, C. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00350-8 · Cited by 4
Is there a role for digoxin in atrial fibrillation without heart failure?
Master, J., & Schweitzer, P. (2009) · PubMed · Cited by 4
Atrial fibrillation management: evaluating rate vs rhythm control
Nguyen, T. L., Jolly, U. S., Sidhu, K., Yee, R. K., & Leong‐Sit, P. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2016.1164033 · Cited by 4
Is There Still a Role for Digoxin in the Management of Atrial Fibrillation?
Washam, J. B., & Patel, M. R. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1047-y · Cited by 4
Non-investigational antiarrhythmic drugs: long-term use and limitations
Gjesdal, K. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330902927647 · Cited by 4
Characteristics and Treatment of Atrial Fibrillation with Respect to the Presence or Absence of Heart Failure. Insights from the Multicenter Polish Atrial Fibrillation (POL-AF) Registry
Gawalko, M. M., Budnik, M., Gorczyca−Michta, I., Jelonek, O. E., Uziębło‐Życzkowska, B., Maciorowska, M., Wójcik, M., Błaszczyk, R. T., Tokarek, T., Rajtar-Salwa, R., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071341 · Cited by 3
The year in cardiovascular medicine 2021: arrhythmias
Crijns, H. J. G. M., Sanders, P., Albert, C. M., & Lambiase, P. D. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac007 · Cited by 3
Atrial fibrillation in heart failure: Current treatment of patients with remodeled atria
Neuberger, H., Reil, J., Adam, O., Laufs, U., Mewis, C., & Böhm, M. (2008) · Current Heart Failure Reports · doi:10.1007/s11897-008-0033-x · Cited by 3
Digoxin Toxicity Caused by an Interaction with the Novel Hepatitis C Medication Ledipasvir/Sofosbuvir
Valentino, M. A. (2016) · Journal of Innovations in Cardiac Rhythm Management · doi:10.19102/icrm.2016.070405 · Cited by 3
A pharmacokinetic study of digoxin holiday dosing practice in Egypt: A prospective-randomized trial
Shabasy, S. A. A., Abbassi, M., Mohamed, M., & Farid, S. F. (2016) · Bulletin of Faculty of Pharmacy Cairo University · doi:10.1016/j.bfopcu.2016.04.004 · Cited by 3
Digoxin or digoxin prescribed patient? Randomized trials are essential to discriminate the principal risk factor for the association of digoxin and increased mortality
Yildiz, A., & Soydinç, S. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.03.029 · Cited by 3
2018 Korean Heart Rhythm Society Guidelines for The Rate Control of Atrial Fibrillation
Lim, W., Choi, E., Joung, B., & Choi, K. (2018) · Korean Journal of Medicine · doi:10.3904/kjm.2018.93.2.133 · Cited by 2
The Bad Reputation of Digoxin in Atrial Fibrillation—Causality or Bias? Nationwide Nested Case-Control Study
Holt, A., Strange, J. E., Hansen, M. L., Lamberts, M., & Rasmussen, P. V. (2025) · American Journal of Medicine Open · doi:10.1016/j.ajmo.2025.100093 · Cited by 2
Increased mortality in patients with secondary diagnosis of atrial fibrillation: Report from Chinese AF registry
Shao, X., Yang, Y., Zhu, J., Yu, L., & Liu, L. (2020) · Annals of Noninvasive Electrocardiology · doi:10.1111/anec.12774 · Cited by 2
Digoxin use and outcomes after myocardial infarction in patients with atrial fibrillation
Kytö, V., Saraste, A., Rautava, P., & Tornio, A. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13733 · Cited by 1
Identifying Temporal Changes to the Prescribing of Anti‐Arrhythmics for Atrial Fibrillation
Yip, A. L. K., & Bajorek, B. V. (2010) · Journal of Pharmacy Practice and Research · doi:10.1002/j.2055-2335.2010.tb00561.x · Cited by 1
Digoxin Loading Doses and Serum Digoxin Concentrations for Rate Control of Atrial Arrhythmias in Critically Ill Patients
Ahuja, T., Saadi, R., Papadopoulos, J., Bernard, S., Pashun, R. A., Horowitz, J. M., Yuriditsky, E., & Merchan, C. (2024) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001648 · Cited by 1
Clarity and controversy around rate control in AF, the orphan child in AF therapeutics
Aguilar, M., & Nattel, S. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.11.024 · Cited by 1

Authors: Hallberg, P., Lindbäck, J., Lindahl, B., Stenestrand, U., Melhus, H., & for the RIKS-HIA group
Affiliations: Uppsala University (SE)
Linköping University Hospital (SE)
Corresponding author: Hallberg, Pär
ORCID: Hallberg, Pär
Lindbäck, Johan
Lindahl, Bertil
Melhus, Håkan
Venue: European Journal of Clinical Pharmacology
Publisher: Springer Science and Business Media LLC
Published: 2007-08-08
Volume: 63
Issue: 10
Pages: 959-971
ISSN: 0031-6970 (ISSN-L)
1432-1041
DOI: 10.1007/s00228-007-0346-9
OpenAlex: W1967375232
Cited by: 113
References: 44
Citations by year: 2025: 2 · 2024: 2 · 2022: 5 · 2021: 8 · 2020: 7 · 2019: 5 · 2018: 8 · 2017: 4 · 2016: 16 · 2015: 19 · 2014: 10 · 2013: 4 · 2012: 5
FWCI: 3.51
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: European Journal of Clinical Pharmacology (publishedVersion)
PubMed (publishedVersion)
Funders: Hjärt-Lungfonden
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
Keywords: digoxin, atrial fibrillation, mortality, congestive heart failure, coronary care unit admission, rhythm control, rate control, cardiovascular risk factors
MeSH terms: Aged, Aged, 80 and over, Anti-Arrhythmia Agents, Atrial Fibrillation, Creatinine, Digoxin, Female, Heart Failure, Humans, Male, Myocardial Infarction, Prospective Studies, Registries, Research Design, Risk Factors, Stroke Volume, Sweden, Time Factors, Proportional Hazards Models, Ventricular Function, Left, Treatment Outcome, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Digoxin and mortality in atrial fibrillation: a prospective cohort study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks